Elan Prialt NDA Amendment Puts Drug On Schedule For Early 2005 Launch

Amendment sets user fee date in December. Submitted Phase III study, which FDA requested in its second “approvable” letter for Prialt, shows significant results for lower doses of the non-opioid analgesic.